Astellas to bring OSI fully into the fold by mid-2011
This article was originally published in Scrip
Executive Summary
Astellas expects to complete the integration of its US acquisition OSI Pharmaceuticals by the end of June next year, by which time a number of restructuring moves associated with the transaction will have taken place.
You may also be interested in...
Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko
Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.